Breast NeoplasmsConsensusCOVID-19
Dr. Vilija N. Avizonis, MD
NPI1003865932PAC ID9032017355
- Medicare services, 2024
- 723
- Medicare patients, 2024
- 144
- Part D claims, 2024
- 105
- Publications
- 6
- Clinical trials
- 7
- Practice address
- 1121 E 3900 S, Salt Lake City, UT 84124
- Practice phone
- Call (801) 269-0231
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Utah Cancer Specialists
Salt Lake City, Utah
Find Dr. Avizonis' professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Vilija N. Avizonis is a radiation oncologist in Salt Lake City, Utah
Dr. Avizonis practices at Utah Cancer Specialists in Salt Lake City, Utah.
Dr. Avizonis' NPI, 1003865932, was assigned on May 8, 2006. Dr. Avizonis graduated from University of New Mexico School of Medicine in 1986. Dr. Avizonis holds Utah license 176911-1205.
NPI and contact details
- NPI
- 1003865932NPI Registry (opens in a new tab)
- Medicare PAC ID
- 9032017355
- NPI enumeration date
- May 8, 2006
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Practice phone
- (801) 269-0231
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Female
- Estimated age
- 66
- Medical school graduation
- 1986
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Practice Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Vilija N. Avizonis practices at Utah Cancer Specialists in Salt Lake City, Utah
Dr. Avizonis' primary practice is Utah Cancer Specialists, at 1121 E 3900 S, Salt Lake City, UT 84124 in Salt Lake County. The practice phone is (801) 269-0231.
- Utah Cancer Specialists1121 E 3900 S, Salt Lake City, UT 84124 · Salt Lake CountyPhone(801) 269-0231
Sources: NPPES NPI Registry (CMS); and Dmand AI Practice Data
Dr. Vilija N. Avizonis is affiliated with 4 sites of care and 2 medical groups
Dr. Avizonis' primary practice is Utah Cancer Specialists in Salt Lake City, Utah. Dr. Avizonis is also affiliated with Intermountain Medical Center. The medical group on file is Utah Cancer Specialists. Dmand AI also links Dr. Avizonis to 2 more group practices and clinics and 1 medical group, each named with a free account.
Utah Cancer SpecialistsPrimary
Sources: NPPES NPI Registry (CMS); Dmand AI Practice Data; and Dmand AI Affiliation Data
Dmand AI tracks the EHR system at Dr. Vilija N. Avizonis' practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Avizonis practices, 3 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Utah Cancer Specialists | Available with a free account |
| +3 more sites and 1 medical group | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every site where Dr. Avizonis practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Vilija N. Avizonis is one of 59 radiation oncologists in Utah
Radiation oncology is Dr. Avizonis' primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Avizonis is licensed in Utah.
Specialties and state licenses
- Radiation oncology, UtahPrimary
Radiation oncologists near Dr. Avizonis
Counts of radiation oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Vilija N. Avizonis billed Medicare for 723 services in 2024
CMS data shows 723 Medicare services from Dr. Avizonis across 14 procedure codes in 2024, for 144 Medicare patients. Medicare paid $56,359 for them.
Medicare services, 2024723
Medicare patients144
Paid by Medicare$56,359
Procedure codes14
Dr. Avizonis' Medicare services by type, 2023 to 2024
- 2023
- 2024
- Imaging
- 2023: 3252024: 54568%
- Office and hospital visits
- 2023: 1002024: 14040%
- Other services
- 2023: 172024: 38124%
Where Dr. Avizonis' Medicare services took place, 2024
- In an office35950%
- In a facility36450%
Dr. Avizonis compared with the Utah median for radiation oncologists, 2024
- Dr. Avizonis
- Utah median
- Medicare services
- 723vs 1,03330% below
- Medicare patients
- 144vs 17216% below
- Part D claims
- 40vs 5629% below
Medians across 53 radiation oncologists in Utah with Dmand AI profiles that report each measure.
Dr. Avizonis' most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Avizonis?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Avizonis and other radiation oncologists in Utah.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Vilija N. Avizonis treated 144 Medicare patients in 2024, average age 74
CMS counts 144 Medicare patients who saw Dr. Avizonis in 2024. The largest group is 65 to 74, with 78 patients. 64% of them have high blood pressure, and 62% have high cholesterol. Their average risk score is 1.37, where 1.00 is the Medicare average.
Across all payers, Dmand AI patient panel data puts Dr. Avizonis' median patient age at 69, with 56% women.
Medicare patients, 2024144
Average age74
Average risk score1.37
Dr. Avizonis' Medicare patients by age, 2024
CMS leaves out age groups with fewer than 11 patients.
Dr. Avizonis' Medicare patients by sex, 2024
- Women8861%
- Men5639%
Chronic conditions among Dr. Avizonis' Medicare patients, 2024
- High blood pressure64%
- High cholesterol62%
- Cancer60%
- Arthritis40%
- Mood disorders25%
- Depression24%
- Diabetes24%
- Anxiety22%
Share of Medicare patients with each condition. A patient can have several.
Dr. Avizonis' patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 69
Patient panel by sex, all payers
- Women56%
- Men43%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Vilija N. Avizonis wrote 105 Medicare Part D claims in 2024
In 2024, Dr. Avizonis wrote 105 Medicare Part D claims for 47 patients. 91% of them were for generic drugs. CMS names the drug for 40 of them, across 2 drugs with 11 or more claims each, at $594 in total drug cost. In 2022, CMS named 16 claims across 1 drug.
Part D claims, 2024105
Drugs named by CMS2
Total drug cost$594
Part D patients47
Dr. Avizonis' Part D claims by kind of drug, 2024
- Generic96 claims91%
- Brand-name and other9 claims9%
Dr. Avizonis' most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Drug classes CMS tracks in Dr. Avizonis' Part D claims, 2024
- Opioids18%19 of 105 claims
Share of all Part D claims for each drug class CMS reports on. Classes with no claims are left out.
Part D claims for drugs CMS names, 2022 to 2024
- 2022
- 2024
- Claims for drugs CMS names
- 2022: 162024: 40150%
Drugs named by CMS: 2 in 2024, 1 in 2022.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Vilija N. Avizonis scored 87 out of 100 in Medicare's MIPS program for 2024
CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Avizonis for performance year 2024, reported as part of a group. Dr. Avizonis accepts Medicare assignment, so Medicare's approved amount is taken as full payment.
- Accepts Medicare assignment
- Yes
Dr. Avizonis' MIPS scores, performance year 2024
- 87of 100Final score
- 77.3of 100Quality
- 90of 100Promoting Interoperability
- 40of 100Improvement Activities
- 78of 100Cost
Each score is out of 100. The final score weighs the categories CMS scored for this clinician.
Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026
For MedTech and pharma teams
Find radiation oncologists like Dr. Avizonis by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Vilija N. Avizonis has 6 publications on record
Dmand AI links 6 papers to Dr. Avizonis, published from 2014 to 2025. 2015 was the busiest year, with 2. The most frequent topics are Carcinoma, Squamous Cell and Radiotherapy, Adjuvant. Dr. Avizonis has published most often in Am J Clin Oncol. Dr. Avizonis' most frequent co-authors are Christopher James Anker, MD, Adel K. El-Naggar, MD, PhD and Carole Fakhry, MD.
Papers6
Years published2014 to 2025
Dr. Avizonis' papers by year, 2014 to 2025
Topics Dr. Avizonis writes about most
- Carcinoma, Squamous Cell
- Radiotherapy, Adjuvant
Dr. Avizonis' most frequent co-authors
- Christopher James Anker, MD2 shared papers
- Adel K. El-Naggar, MD, PhD2 shared papers
- Carole Fakhry, MD2 shared papers
Recent publications by Dr. Avizonis
Carcinoma, Squamous CellNeoplasm ProteinsOropharyngeal Neoplasms
Am J Clin Oncol
Bell PalsyCarcinomaChemoradiotherapy, Adjuvant
See who Dr. Avizonis researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Avizonis works with, so you can find a warm path to the right radiation oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Vilija N. Avizonis has worked on 7 clinical trials
Dmand AI links Dr. Avizonis to 7 clinical trials, 2 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Tongue Neoplasms, Tongue Diseases and Breast Neoplasms. NRG Oncology sponsors the most, 2.
Clinical trials with Dr. Avizonis by phase
- NonePhase 1: no trials
- 2Phase 2: 2 trials
- 2Phase 2/3: 2 trials
- 2Phase 3: 2 trials
- NonePhase 4: no trials
Conditions in Dr. Avizonis' trials
- Tongue Neoplasms
- Tongue Diseases
- Breast Neoplasms
- Carcinoma, Lobular
- Nasopharyngeal Carcinoma
Investigators on the most trials with Dr. Avizonis
- Jonathan Jay Beitler, MBA, MD5 shared trials
- Samir Narayan, MD5 shared trials
- Kevin P. Redmond, MD5 shared trials
Recent clinical trials with Dr. Avizonis
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer (opens in a new tab)
Active, not recruitingPhase 2/3
Oropharyngeal NeoplasmsPharyngeal NeoplasmsCisplatinNivolumabImage Guided Radiation Therapy
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients with Stage IIa-IIIa Breast Cancer (opens in a new tab)
Active, not recruitingPhase 3
Carcinoma, LobularCarcinoma, Ductal, BreastHypofractionated Radiation TherapyRadiation Therapy
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA (opens in a new tab)
Active, not recruitingPhase 2/3
Nasopharyngeal CarcinomaNasopharyngeal DiseasesCisplatinFluorouracilGemcitabine Hydrochloride
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery (opens in a new tab)
Active, not recruiting
Breast NeoplasmsBreast Diseaseschestwall XRTregional nodal XRTWBI
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer (opens in a new tab)
Active, not recruitingPhase 3
Tongue NeoplasmsTongue DiseasesCetuximabIntensity-modulated radiation therapy
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Vilija N. Avizonis received $865 in industry payments from 2016 to 2025
CMS Open Payments shows 24 general payments to Dr. Avizonis from 11 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Varian Medical Systems, Inc. paid the most, $258.
General payments to Dr. Avizonis by program year, 2016 to 2025
Companies that paid Dr. Avizonis the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Vilija N. Avizonis graduated from University of New Mexico School of Medicine
Dr. Avizonis graduated from University of New Mexico School of Medicine in 1986.
- Medical school
Source: Dmand AI Professional Profile Data
Sources for Dr. Vilija N. Avizonis's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice Data |
| Primary practice, affiliations and health system | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice DataDmand AI Affiliation Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Vilija N. Avizonis
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Vilija N. Avizonis' NPI number?
Dr. Vilija N. Avizonis' NPI number is 1003865932. It was assigned on May 8, 2006, and it is active in the NPI Registry.
What kind of doctor is Dr. Vilija N. Avizonis?
Dr. Vilija N. Avizonis is a radiation oncologist in Salt Lake City, Utah. The primary specialty in the NPI Registry is Radiation Oncology Physician (taxonomy code 2085R0001X).
Where does Dr. Vilija N. Avizonis practice?
Dr. Avizonis practices at 1121 E 3900 S, Salt Lake City, UT 84124. Dr. Avizonis' primary practice is Utah Cancer Specialists in Salt Lake City, Utah. Dmand AI also links Dr. Avizonis to 2 group practices and clinics and 1 medical group.
What is Dr. Vilija N. Avizonis' office phone number?
The practice phone on file for Dr. Avizonis is (801) 269-0231.
What is Dr. Vilija N. Avizonis' medical license number?
Dr. Avizonis holds Utah license 176911-1205.
Which hospitals is Dr. Vilija N. Avizonis affiliated with?
Dr. Avizonis is affiliated with Intermountain Medical Center.
What medical group is Dr. Vilija N. Avizonis part of?
Dr. Avizonis is linked to Utah Cancer Specialists. Dmand AI links Dr. Avizonis to 1 more medical group.
Does Dr. Vilija N. Avizonis accept Medicare?
Yes. CMS data shows Dr. Avizonis billed Medicare for 723 services in 2024, and Dr. Avizonis accepts Medicare assignment.
What is Dr. Vilija N. Avizonis' MIPS score?
Dr. Avizonis' MIPS final score for performance year 2024 is 87 out of 100, reported as part of a group.
How many Medicare patients does Dr. Vilija N. Avizonis see?
CMS counts 144 Medicare patients who saw Dr. Avizonis in 2024, with an average age of 74.
Show 7 more questionsShow fewer questions
What services does Dr. Vilija N. Avizonis bill to Medicare?
In 2024, Dr. Avizonis' most billed Medicare services were radiation oncology (77300), radiation oncology (77334) and radiation oncology (77427).
Where did Dr. Vilija N. Avizonis go to medical school?
Dr. Avizonis graduated from University of New Mexico School of Medicine in 1986.
What drugs does Dr. Vilija N. Avizonis prescribe most?
In 2024 Medicare Part D data, Dr. Avizonis' most prescribed drugs by claims were Lidocaine HCl Viscous and Gabapentin.
Has Dr. Vilija N. Avizonis received payments from drug or device companies?
CMS Open Payments shows $865 in general payments to Dr. Avizonis from 11 companies from 2016 to 2025. The largest total came from Varian Medical Systems, Inc.
How long has Dr. Vilija N. Avizonis been practicing?
Dr. Avizonis graduated from medical school in 1986, 40 years ago.
Does Dr. Vilija N. Avizonis do research?
Dmand AI links 6 publications to Dr. Avizonis, published from 2014 to 2025. Dr. Avizonis has worked on 7 clinical trials.
Who does Dr. Vilija N. Avizonis publish with?
Dr. Avizonis' most frequent co-authors are Christopher James Anker, MD (2 shared papers), Adel K. El-Naggar, MD, PhD (2 shared papers) and Carole Fakhry, MD (2 shared papers).
Selling to radiation oncology practices?
See radiation oncologists in Utah by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card